Breast Cancer Research投稿须知

期刊简介

《Breast Cancer Research》是由BioMed Central出版社于1999年创办的英文国际期刊（ISSN: 1465-542X，E-ISSN: 1465-542X），该期刊长期致力于肿瘤学领域的创新研究，主要研究方向为ONCOLOGY。作为SCIE收录期刊（JCR分区 Q1，中科院 1区），本刊采用OA开放获取模式（OA占比1%），以发表肿瘤学领域等方向的原创性研究为核心（研究类文章占比94.37%%）。凭借严格的同行评审与高效编辑流程，期刊年载文量精选控制在142篇，确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库，为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Breast Cancer Research审稿周期约为一般,3-8周。该刊近年未被列入国际预警名单，年发文量约142篇，录用竞争适中，主题需确保紧密契合医学前沿。投稿策略提示：避开学术会议旺季投稿以缩短周期，语言建议专业润色提升可读性。

医学大类学科
English 出版语言
否是否预警
SCIE 期刊收录
142 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊	综述期刊	大类学科	小类学科
否	否	医学 1区	ONCOLOGY 肿瘤学 2区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊	综述期刊	大类学科	小类学科
是	否	医学 1区	ONCOLOGY 肿瘤学 2区

JCR分区

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q1	49 / 322	84.9%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q1	47 / 322	85.56%

CiteScore

SJR

SNIP

CiteScore 排名

CiteScore：12

SJR：2.578

SNIP：1.865

学科类别	分区	排名	百分位
大类：Medicine 小类：Oncology	Q1	45 / 404	88%
大类：Medicine 小类：Cancer Research	Q1	37 / 230	84%

期刊发文

Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling
Author: Liu, Heshu; Yan, Rui; Xiao, Zeru; Huang, Xuying; Yao, Jiannan; Liu, Jian; An, Guangyu; Ge, Yang

Journal: BREAST CANCER RESEARCH. 2023; Vol. 25, Issue 1, pp. -. DOI: 10.1186/s13058-023-01642-3
MTX-PEG-modified CG/DMMA polymeric micelles for targeted delivery of doxorubicin to induce synergistic autophagic death against triple-negative breast cancer
Author: Cao, Zhiwen; Liu, Rui; Li, Yang; Luo, Xinyi; Hua, Zhenglai; Wang, Xiangpeng; Xue, Zeyu; Zhang, Zhengjia; Lu, Cheng; Lu, Aiping; Liu, Yuanyan

Journal: BREAST CANCER RESEARCH. 2023; Vol. 25, Issue 1, pp. -. DOI: 10.1186/s13058-022-01599-9
Association between human blood metabolome and the risk of breast cancer
Author: Wang, Yu; Liu, Fanghua; Sun, Lulu; Jia, Yiming; Yang, Pinni; Guo, Daoxia; Shi, Mengyao; Wang, Aili; Chen, Guo-Chong; Zhang, Yonghong; Zhu, Zhengbao

Journal: BREAST CANCER RESEARCH. 2023; Vol. 25, Issue 1, pp. -. DOI: 10.1186/s13058-023-01609-4
METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer
Author: Ouyang, Dengjie; Hong, Tao; Fu, Mengdie; Li, Yitong; Zeng, Liyun; Chen, Qitong; He, Hongye; Wen, Ying; Cheng, Yan; Zhou, Meirong; Zou, Qiongyan; Yi, Wenjun

Journal: BREAST CANCER RESEARCH. 2023; Vol. 25, Issue 1, pp. -. DOI: 10.1186/s13058-022-01598-w
CMTM7 inhibits breast cancer progression by regulating Wnt/beta-catenin signaling
Author: Chen, Zhao-Hui; Tian, Yao; Zhou, Guang-Lei; Yue, Hao-Ran; Zhou, Xue-Jie; Ma, Hai-Yan; Ge, Jie; Wang, Xin; Cao, Xu-Chen; Yu, Yue

Journal: BREAST CANCER RESEARCH. 2023; Vol. 25, Issue 1, pp. -. DOI: 10.1186/s13058-023-01620-9
RET signaling in breast cancer therapeutic resistance and metastasis
Author: Pecar, Geoffrey; Liu, Simeng; Hooda, Jagmohan; Atkinson, Jennifer M. M.; Oesterreich, Steffi; Lee, Adrian V. V.

Journal: BREAST CANCER RESEARCH. 2023; Vol. 25, Issue 1, pp. -. DOI: 10.1186/s13058-023-01622-7
Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low
Author: Hu, Xi'e; Yang, Ping; Chen, Songhao; Wei, Gang; Yuan, Lijuan; Yang, Zhenyu; Gong, Li; He, Li; Yang, Lin; Peng, Shujia; Dong, Yanming; He, Xianli; Bao, Guoqiang

Journal: BREAST CANCER RESEARCH. 2023; Vol. 25, Issue 1, pp. -. DOI: 10.1186/s13058-023-01639-y
PKC-zeta mediated reduction of the extracellular vesicles-associated TGF-beta 1 overcomes radiotherapy resistance in breast cancer
Author: Zhang, Fayun; Zheng, Zifeng; Wang, Luoyang; Zeng, Wenfeng; Wei, Wenjing; Zhang, Chunling; Zhao, Ziran; Liang, Wei

Journal: BREAST CANCER RESEARCH. 2023; Vol. 25, Issue 1, pp. -. DOI: 10.1186/s13058-023-01641-4

Breast Cancer Research

乳腺癌研究

期刊简介

投稿提示

中科院分区

JCR分区

CiteScore

期刊发文

相关期刊

怎样选择期刊

投稿相关问题

投稿后咨询